Ethical, legal and social implications of incorporating personalized medicine into healthcare.

As research focused on personalized medicine has developed over the past decade, bioethics scholars have contemplated the ethical, legal and social implications of this type of research. In the next decade, there will be a need to broaden the focus of this work as personalized medicine moves into clinical settings. We consider two broad issues that will grow in importance and urgency. First, we analyze the consequences of the significant increase in health information that will be brought about by personalized medicine. Second, we raise concerns about the potential of personalized medicine to exacerbate existing disparities in healthcare.

[1]  Susan S. Woods,et al.  Promise of and potential for patient-facing technologies to enable meaningful use. , 2011, American journal of preventive medicine.

[2]  M. Wynia,et al.  Dreams and Nightmares: Practical and Ethical Issues for Patients and Physicians Using Personal Health Records , 2010, Journal of Law, Medicine & Ethics.

[3]  R. Gramling,et al.  Predictive genetics in primary care: expectations for the motivational impact of genetic testing affects the importance family physicians place on screening for familial cancer risk. , 2003 .

[4]  E. Juengst,et al.  Personalized genomic medicine and the rhetoric of empowerment. , 2012, The Hastings Center report.

[5]  R. Green,et al.  How could disclosing incidental information from whole-genome sequencing affect patient behavior? , 2013, Personalized medicine.

[6]  R Saracci,et al.  Directive of the European Parliament and of the council on the protection of individuals with regard to the processing of personal data and on the free movement of such data. The International Epidemiological Association-IEA European Epidemiological Group. , 1995, International journal of epidemiology.

[7]  Y. Joly,et al.  Genetic information and insurance underwriting: Contemporary issues and approaches in the global economy , 2009 .

[8]  R. Verbrugge,et al.  Adoption of Pharmacogenomic Testing by US Physicians: Results of a Nationwide Survey , 2012, Clinical pharmacology and therapeutics.

[9]  F. Collins,et al.  Merging and emerging cohorts: Necessary but not sufficient , 2007, Nature.

[10]  Celeste M Condit,et al.  Genetic research and health disparities. , 2004, JAMA.

[11]  A. Need,et al.  Next generation disparities in human genomics: concerns and remedies. , 2009, Trends in genetics : TIG.

[12]  L. Hood,et al.  Predictive, personalized, preventive, participatory (P4) cancer medicine , 2011, Nature Reviews Clinical Oncology.

[13]  E. Rimm,et al.  A prospective study of 2 major age-related macular degeneration susceptibility alleles and interactions with modifiable risk factors. , 2007, Archives of ophthalmology.

[14]  Barbara Prainsack,et al.  Personal genomes: Misdirected precaution , 2008, Nature.

[15]  Mark A Rothstein,et al.  Compelled disclosure of health information: protecting against the greatest potential threat to privacy. , 2006, JAMA.

[16]  L. Hernandez.  Implications of Genomics for Public Health: Workshop Summary , 2005 .

[17]  Marc S. Williams,et al.  ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing , 2013, Genetics in Medicine.

[18]  M. Rothstein,et al.  What is genetic discrimination, and when and how can it be prevented? , 2001, Genetics in Medicine.

[19]  R. Bhopal,et al.  Pharmacogenetics and ethnically targeted therapies , 2005, BMJ : British Medical Journal.

[20]  F. Collins,et al.  A vision for the future of genomics research , 2003, Nature.

[21]  Katherine Newman,et al.  Socioeconomic disparities in health: pathways and policies. , 2002, Health affairs.

[22]  Zachary A. Szpiech,et al.  Genome-wide association studies in diverse populations , 2010, Nature Reviews Genetics.

[23]  M. Rothstein,et al.  Genetic Exceptionalism & Legislative Pragmatism , 2005, The Hastings Center report.

[24]  B. Knoppers,et al.  Recommendations for returning genomic incidental findings? We need to talk! , 2013, Genetics in Medicine.

[25]  M. Rothstein.  Currents in Contemporary Bioethics , 2003, Journal of Law, Medicine & Ethics.

[26]  Mark A. Rothstein,et al.  Compelled Authorizations for Disclosure of Health Records: Magnitude and Implications , 2007, The American journal of bioethics : AJOB.

[27]  M. Langanke,et al.  Gesundheitliche Eigenverantwortung im Kontext Individualisierter Medizin , 2013, Ethik in der Medizin.

[28]  E. Mardis.  The $1,000 genome, the $100,000 analysis? , 2010, Genome Medicine.

[29]  Autonomy and Paternalism in Health Policy: Currents in Contemporary Bioethics , 2014, Journal of Law, Medicine & Ethics.

[30]  A. Kurian.  BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications , 2010, Current opinion in obstetrics & gynecology.

[31]  M. Khoury.  Dealing With the Evidence Dilemma in Genomics and Personalized Medicine , 2010, Clinical pharmacology and therapeutics.

[32]  K. Brothers,et al.  Motivation in the age of genomics: why genetic findings of disease susceptibility might not motivate behavior change , 2013, Life Sciences, Society and Policy.

[33]  G. Marchant,et al.  Personalized medicine and genetic malpractice , 2013, Genetics in Medicine.

[34]  N. Agahi,et al.  Socioeconomic inequalities in health after age 50: are health risk behaviors to blame? , 2014, Social science & medicine.

[35]  B. Knoppers.  Duty to recontact: a legal harbinger? , 2001, American journal of medical genetics.

[36]  S. Lee.  Racializing drug design: implications of pharmacogenomics for health disparities. , 2005, American journal of public health.

[37]  Mark A. Rothstein,et al.  Genetic Exceptionalism and Legislative Pragmatism , 2007, Journal of Law, Medicine & Ethics.

[38]  Abdallah S. Daar,et al.  Pharmacogenetics and geographical ancestry: implications for drug development and global health , 2005, Nature Reviews Genetics.

[39]  Kyle L. Galbraith.  What's so meaningful about meaningful use? , 2013, The Hastings Center report.

[40]  Y. Bombard,et al.  Genetic discrimination: international perspectives. , 2012, Annual review of genomics and human genetics.

[41]  Autonomy and Paternalism in Health Policy , 2014 .

[42]  B. Knoppers,et al.  Personalized medicine and access to health care: potential for inequitable access? , 2012, European Journal of Human Genetics.

[43]  N. Risch,et al.  The importance of race and ethnic background in biomedical research and clinical practice. , 2003, The New England journal of medicine.

[44]  A. Beitelshees,et al.  Cost‐Effectiveness of Cytochrome P450 2C19 Genotype Screening for Selection of Antiplatelet Therapy with Clopidogrel or Prasugrel , 2012, Pharmacotherapy.

[45]  T. Beauchamp,et al.  Principles of biomedical ethics , 1991 .

[46]  W. Burke,et al.  Comprar Achieving Justice in Genomic Translation Re-Thinking the Pathway to Benefit | Susan Brown Trinidad | 9780195390384 | Oxford University Press , 2011 .